Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila Akk11
- Development stage
- Preclinical
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Akkermansia muciniphila Akk11 is a specific strain of the gut bacterium *Akkermansia muciniphila* being investigated as a live biotherapeutic product (LBP) for the treatment of Parkinson's disease (PD). It exerts neuroprotective effects through the gut-brain axis by modulating the intestinal environment and systemic inflammatory responses. Preclinical studies in MPTP-induced PD mouse models demonstrate that Akk11 administration significantly improves motor deficits, reduces the loss of dopaminergic neurons in the substantia nigra, and suppresses microglial activation. The primary mechanism of action involves the inhibition of the NLRP3 inflammasome pathway in microglia, which leads to a reduction in the production of pro-inflammatory cytokines such as IL-1β and TNF-α. Additionally, Akk11 helps maintain colonic barrier integrity, addressing the gut dysbiosis often associated with PD progression.
- Other names
- Akkermansia muciniphila strain Akk11
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Akkermansia muciniphila Akk11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila Akk11.